These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 34121230)

  • 1. Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant-treated rectal adenocarcinoma.
    Aherne S; Donnelly M; Ryan ÉJ; Davey MG; Creavin B; McGrath E; McCarthy A; Geraghty R; Gibbons D; Nagtegaal I; Lugli A; Kirsch R; Martin ST; Winter DC; Sheahan K;
    Histopathology; 2024 Aug; 85(2):224-243. PubMed ID: 38629323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
    Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
    Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of T lymphocyte subgroups (CD4 and CD8) in lung cancer patients after neoadjuvant chemotherapy.
    Elicora A; Yaprak Bayrak B; Vural C; Sezer HF; Uzun Erkal S; Metin E
    J Cardiothorac Surg; 2024 Mar; 19(1):113. PubMed ID: 38468248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
    Lonie JM; Brosda S; Bonazzi VF; Aoude LG; Patel K; Brown I; Sharma S; Lampe G; Addala V; Koufariotis LT; Wood S; Waddell N; Dolcetti R; Barbour AP
    Front Immunol; 2023; 14():1220129. PubMed ID: 37965317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paneth cell differentiation associated with neoadjuvant therapy in esophageal adenocarcinoma.
    Ramineni M; Findeis SK; Ye J; Hao Y
    Am J Clin Pathol; 2024 Aug; ():. PubMed ID: 39110451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial transcriptomic analysis reveals local effects of intratumoral fusobacterial infection on DNA damage and immune signaling in rectal cancer.
    Duggan WP; Kisakol B; Woods I; Azimi M; Dussmann H; Fay J; O'Grady T; Maguire B; Reynolds IS; Salvucci M; Slade DJ; McNamara DA; Burke JP; Prehn JHM
    Gut Microbes; 2024; 16(1):2350149. PubMed ID: 38709233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of tumor budding in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis.
    Li J; Ma Y; Wen L; Zhang G; Huang C; Wang J; Yao X
    Syst Rev; 2024 Jan; 13(1):22. PubMed ID: 38191437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tumour budding on adjuvant chemotherapy in colorectal cancer.
    Xie H; Zeng Z; Hou Y; Ye F; Cai T; Cai Y; Xiong L; Li W; Liu Z; Liang Z; Luo S; Zheng X; Huang L; Liu H; Kang L
    BJS Open; 2024 Jan; 8(1):. PubMed ID: 38190579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological Significances and Prognostic Role of Intratumoral Budding in Colorectal Cancers.
    Kang G; Pyo JS; Kim NY; Kang DW
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral Budding in Pretreatment Biopsies, among Tumor Microenvironmental Components, Can Predict Prognosis and Neoadjuvant Therapy Response in Colorectal Adenocarcinoma.
    Yim K; Jang WM; Cho U; Sun S; Chong Y; Seo KJ
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888645
    [No Abstract]   [Full Text] [Related]  

  • 11. Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer.
    Sano S; Akiyoshi T; Yamamoto N; Hiyoshi Y; Mukai T; Yamaguchi T; Nagasaki T; Taketomi A; Fukunaga Y; Kawachi H
    Clin Colorectal Cancer; 2023 Dec; 22(4):411-420.e1. PubMed ID: 37516615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High CD8
    Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
    Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMMUNOREACT 0: Biopsy-based immune biomarkers as predictors of response to neoadjuvant therapy for rectal cancer-A systematic review and meta-analysis.
    Stepanyan A; Fassan M; Spolverato G; Castagliuolo I; Scarpa M; Scarpa M;
    Cancer Med; 2023 Sep; 12(17):17878-17890. PubMed ID: 37537787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response in colorectal carcinoma: a review of its significance as a predictive and prognostic biomarker.
    Bell PD; Pai RK
    Histopathology; 2022 Dec; 81(6):696-714. PubMed ID: 35758208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined histopathological risk score using TP53 protein expression, CD8
    Chen W; Farchoukh L; Seigh L; Hartman DJ; Pai RK
    Histopathology; 2021 Nov; 79(5):826-835. PubMed ID: 34121230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
    Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
    Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.